Skip to main content
Top
Published in: Clinical Pharmacokinetics 5/2000

01-05-2000 | Leading Article

Choosing the Right Nonsteroidal Anti-Inflammatory Drug for the Right Patient

A Pharmacokinetic Approach

Authors: Dr Neal M. Davies, Neil M. Skjodt

Published in: Clinical Pharmacokinetics | Issue 5/2000

Login to get access

Abstract

Effective use of the growing number of nonsteroidal anti-inflammatory drugs (NSAIDs), a group that has recently been augmented by the introduction of the selective cyclo-oxygenase-2 inhibitors, requires adequate knowledge of their pharmacokinetics.
After oral administration, the absorption of NSAIDs is generally rapid and complete. NSAIDs are highly bound to plasma proteins, specifically to albumin (>90%). The volume of distribution of NSAIDs is low, ranging from 0.1 to 0.3 L/kg, suggesting minimal tissue binding. NSAID binding in plasma can be saturated when the concentration of the NSAID exceeds that of albumin.
Most NSAIDs are metabolised by the liver, with subsequent excretion into urine or bile. Enterohepatic recirculation occurs when a significant amount of an NSAID or its conjugated metabolites are excreted into the bile and then reabsorbed in the distal intestine. NSAID elimination is not dependent on hepatic blood flow. Hepatic NSAID elimination is dependent on the free fraction of NSAID within the plasma and the intrinsic enzyme activities of the liver. Renal elimination is not an important elimination pathway for NSAIDs, except for azapropazone. The plasma half-life of NSAIDs ranges from 0.25 to >70 hours, indicating wide differences in clearance rates. Hepatic or renal disease can alter NSAID protein binding and metabolism. Some NSAIDs with elimination predominantly via acylglucuronidation can have significantly altered disposition. Pharmacokinetics are also influenced by chronobiology, and many NSAIDs exhibit stereoselectivity.
There appear to be relationships between NSAID concentration and effects. At therapeutically equivalent doses, NSAIDs appear to be equally efficacious. The major differences between NSAIDs are their therapeutic half-lives and safety profiles. NSAIDs undergo drug interactions through protein binding displacement and competition for active renal tubular secretion with other organic acids.
When choosing the right NSAID for the right patient, individual patient-specific and NSAID-specific pharmacokinetic principles should be considered.
Literature
1.
go back to reference Meade EA, Smith WL, DeWitt DL. Differential inhibition of Prostaglandin endoperoxide synthase (cyclooxygenase) iso-zymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1993; 268(9): 6610–4.PubMed Meade EA, Smith WL, DeWitt DL. Differential inhibition of Prostaglandin endoperoxide synthase (cyclooxygenase) iso-zymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1993; 268(9): 6610–4.PubMed
2.
go back to reference Vane JR, Mitchell JA, Appleton I, et al. Inducible isoforms of cyclooxygenase and nitric-oxide synthetase in inflammation. Proc Natl Acad Sci U S A. 1994; 91(6): 2046–50.PubMedCrossRef Vane JR, Mitchell JA, Appleton I, et al. Inducible isoforms of cyclooxygenase and nitric-oxide synthetase in inflammation. Proc Natl Acad Sci U S A. 1994; 91(6): 2046–50.PubMedCrossRef
3.
go back to reference Yamagata K, Andreasson KI, Kaufmann WE, et al. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron. 1993; 11: 371–86.PubMedCrossRef Yamagata K, Andreasson KI, Kaufmann WE, et al. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron. 1993; 11: 371–86.PubMedCrossRef
4.
go back to reference Davies NM, Wallace JL. Selective inhibitors of cyclooxygenase 2: potential in elderly patients. Drugs Aging. 1996; 9(6): 406–17.PubMedCrossRef Davies NM, Wallace JL. Selective inhibitors of cyclooxygenase 2: potential in elderly patients. Drugs Aging. 1996; 9(6): 406–17.PubMedCrossRef
5.
go back to reference Sano HT, Hla JAM, Maier LJ, et al. In vivo cyclooxygenase expression in synovial tissue of patients with rheumatoid arthritis and Osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J Clin Invest. 1997; 89: 97–108.CrossRef Sano HT, Hla JAM, Maier LJ, et al. In vivo cyclooxygenase expression in synovial tissue of patients with rheumatoid arthritis and Osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J Clin Invest. 1997; 89: 97–108.CrossRef
6.
go back to reference Crofford LJ, Wilder RL, Ristimalki AP, et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. J Clin Invest. 1994; 93: 1095–101.PubMedCrossRef Crofford LJ, Wilder RL, Ristimalki AP, et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. J Clin Invest. 1994; 93: 1095–101.PubMedCrossRef
7.
go back to reference Boyce S, Chan CC, Gordon R, et al. L-745,337: a selective inhibitor of cyclooxygenase-2 elicits antinociception but not gastric ulceration in rats. Neuropharmacology. 1994; 33(12): 1609–11.PubMedCrossRef Boyce S, Chan CC, Gordon R, et al. L-745,337: a selective inhibitor of cyclooxygenase-2 elicits antinociception but not gastric ulceration in rats. Neuropharmacology. 1994; 33(12): 1609–11.PubMedCrossRef
8.
go back to reference Heller CA, Ingelfinger JA, Goldman P. Nonsteroidal anti-inflammatory drugs and aspirin: analyzing the scores. Pharma-cotherapy. 1985; 5: 30–8. Heller CA, Ingelfinger JA, Goldman P. Nonsteroidal anti-inflammatory drugs and aspirin: analyzing the scores. Pharma-cotherapy. 1985; 5: 30–8.
9.
go back to reference Baber N, Halliday LDC, van Den Heuvel WJA, et al. Indometh-acin in rheumatoid arthritis: clinical effects, pharmacokinetics and platelet studies in responders and non-responders. Ann Rheum Dis. 1979; 38: 128–37.PubMedCrossRef Baber N, Halliday LDC, van Den Heuvel WJA, et al. Indometh-acin in rheumatoid arthritis: clinical effects, pharmacokinetics and platelet studies in responders and non-responders. Ann Rheum Dis. 1979; 38: 128–37.PubMedCrossRef
10.
go back to reference Capell HA, Knotschnik B, Glass RC. Anti-inflammatory analgesic drug responders and non-responders: a clinico-pharma-cologic study of flurbiprofen. Br J Clin Pharmacol. 1977; 4: 623–4.PubMedCrossRef Capell HA, Knotschnik B, Glass RC. Anti-inflammatory analgesic drug responders and non-responders: a clinico-pharma-cologic study of flurbiprofen. Br J Clin Pharmacol. 1977; 4: 623–4.PubMedCrossRef
11.
go back to reference Walker JS, Sheather-Reif RB, Carmody JJ, et al. Nonsteroidal antiinflammatory drugs in rheumatoid arthritis and Osteoarthritis: support for the concept of ‘responders’ and ‘non-responders’. Arthritis Rheum. 1997; 40(11): 1944–54.PubMedCrossRef Walker JS, Sheather-Reif RB, Carmody JJ, et al. Nonsteroidal antiinflammatory drugs in rheumatoid arthritis and Osteoarthritis: support for the concept of ‘responders’ and ‘non-responders’. Arthritis Rheum. 1997; 40(11): 1944–54.PubMedCrossRef
12.
go back to reference Walker JS, Carmody JJ. Experimental pain in healthy human subjects: gender differences in nociception and in response to Ibuprofen. Anesth Analg. 1998; 86(6): 1257–62.PubMed Walker JS, Carmody JJ. Experimental pain in healthy human subjects: gender differences in nociception and in response to Ibuprofen. Anesth Analg. 1998; 86(6): 1257–62.PubMed
13.
go back to reference Carson JL, Strom BL, Soper KA, et al. The association of nonsteroidal antiinflammatory drugs with upper gastrointestinal tract bleeding. Arch Int Med. 1987; 114: 85–8.CrossRef Carson JL, Strom BL, Soper KA, et al. The association of nonsteroidal antiinflammatory drugs with upper gastrointestinal tract bleeding. Arch Int Med. 1987; 114: 85–8.CrossRef
14.
go back to reference Singh G, Ramey DR, Morfeld D, et al. Comparative toxicity of non-steroidal antiinflammatory agents. Pharmacol Ther. 1994; 62: 175–91.PubMedCrossRef Singh G, Ramey DR, Morfeld D, et al. Comparative toxicity of non-steroidal antiinflammatory agents. Pharmacol Ther. 1994; 62: 175–91.PubMedCrossRef
15.
go back to reference Davies NM, Jamali F, Skeith KJ. Non-steroidal anti-inflammatory drug (NSAID)-induced enteropathy and severe chronic anemia in a patient with rheumatoid arthritis. Arthritis Rheum. 1996; 39(2): 321–4.PubMedCrossRef Davies NM, Jamali F, Skeith KJ. Non-steroidal anti-inflammatory drug (NSAID)-induced enteropathy and severe chronic anemia in a patient with rheumatoid arthritis. Arthritis Rheum. 1996; 39(2): 321–4.PubMedCrossRef
16.
17.
go back to reference Lanza FL, Royer GL, Nelson RS. Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa. N Engl J Med. 1980; 303: 136–8.PubMedCrossRef Lanza FL, Royer GL, Nelson RS. Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa. N Engl J Med. 1980; 303: 136–8.PubMedCrossRef
18.
go back to reference Trondstad RI, Aadland E, Holler T, et al. Gastroscopic findings after treatment with enteric-coated and plain naproxen tablets in healthy subjects. Scand J Gastroenterol. 1985; 20: 239–42.PubMedCrossRef Trondstad RI, Aadland E, Holler T, et al. Gastroscopic findings after treatment with enteric-coated and plain naproxen tablets in healthy subjects. Scand J Gastroenterol. 1985; 20: 239–42.PubMedCrossRef
19.
go back to reference Davies NM. Sustained release and enteric coated NSAIDs: are they really GI safe? J Pharm Pharmaceut Sci. 1999; 2: 139–48. Davies NM. Sustained release and enteric coated NSAIDs: are they really GI safe? J Pharm Pharmaceut Sci. 1999; 2: 139–48.
20.
go back to reference Collins AT, Davies J, Dixon A. A prospective endoscopie study of the effect of Orudis and Oruvail on the upper gastrointestinal tract in patients with Osteoarthritis. Br J Rheumatol. 1988; 27: 106–9.PubMedCrossRef Collins AT, Davies J, Dixon A. A prospective endoscopie study of the effect of Orudis and Oruvail on the upper gastrointestinal tract in patients with Osteoarthritis. Br J Rheumatol. 1988; 27: 106–9.PubMedCrossRef
21.
go back to reference Whitcomb DC. Pathophysiology of nonsteroidal antiinflammatory drug-induced intestinal strictures [letter]. Gastroenterology. 1993; 105(5): 1590.PubMedCrossRef Whitcomb DC. Pathophysiology of nonsteroidal antiinflammatory drug-induced intestinal strictures [letter]. Gastroenterology. 1993; 105(5): 1590.PubMedCrossRef
22.
go back to reference Choi VMI, Coates JE, Chooi J, et al. Small bowel permeability: a variable effect of NSAIDs. Clin Invest Med. 1995; 18: 357–61.PubMed Choi VMI, Coates JE, Chooi J, et al. Small bowel permeability: a variable effect of NSAIDs. Clin Invest Med. 1995; 18: 357–61.PubMed
23.
go back to reference Evans AM, Nation RL, Sansom LN, et al. Stereoselective drug disposition: potential for misinterpretation of drug disposition data. Br J Clin Chem. 1988; 26: 771–80. Evans AM, Nation RL, Sansom LN, et al. Stereoselective drug disposition: potential for misinterpretation of drug disposition data. Br J Clin Chem. 1988; 26: 771–80.
24.
go back to reference Hutt AJ, Caldwell J. The importance of stereochemistry in the Clinical Pharmacokinetics of the 2-arylpropionic acid non-steroidal anti-inflammatory drugs. Clin Pharmacokinet. 1984; 9(4): 371–3.PubMedCrossRef Hutt AJ, Caldwell J. The importance of stereochemistry in the Clinical Pharmacokinetics of the 2-arylpropionic acid non-steroidal anti-inflammatory drugs. Clin Pharmacokinet. 1984; 9(4): 371–3.PubMedCrossRef
25.
go back to reference Jamali F. Pharmacokinetics of enantiomers of chiral non-steroidal anti-inflammatory drugs. Eur J Drug Metab Pharmacokinet. 1988; 13: 1–9.PubMedCrossRef Jamali F. Pharmacokinetics of enantiomers of chiral non-steroidal anti-inflammatory drugs. Eur J Drug Metab Pharmacokinet. 1988; 13: 1–9.PubMedCrossRef
26.
go back to reference Evans AM. Enantioselective pharmacodynamics and pharmacokinetics of chiral non-steroidal anti-inflammatory drugs. Clin Pharmacol. 1992; 42: 237–56. Evans AM. Enantioselective pharmacodynamics and pharmacokinetics of chiral non-steroidal anti-inflammatory drugs. Clin Pharmacol. 1992; 42: 237–56.
27.
go back to reference Brune K, Geisslinger G, Menzel-Sogolowek S. Pure enantiomers of 2-arylpropionic acids: tools in pain research and improved drugs in rheumatology. J Clin Pharmacol. 1992; 32: 944–52.PubMed Brune K, Geisslinger G, Menzel-Sogolowek S. Pure enantiomers of 2-arylpropionic acids: tools in pain research and improved drugs in rheumatology. J Clin Pharmacol. 1992; 32: 944–52.PubMed
28.
go back to reference Jamali F, Mehvar R, Russell AS, et al. Human pharmacokinetics of Ibuprofen enantiomers following different doses and formulations: intestinal chiral inversion. J Pharm Sci. 1991; 81: 221–5.CrossRef Jamali F, Mehvar R, Russell AS, et al. Human pharmacokinetics of Ibuprofen enantiomers following different doses and formulations: intestinal chiral inversion. J Pharm Sci. 1991; 81: 221–5.CrossRef
29.
go back to reference Dwivedi SK, Sattari S, Jamali F, et al. Ibuprofen racemate and enantiomers: phase diagram, solubility and thermodynamic studies. Int J Pharm. 1992; 87: 95–104.CrossRef Dwivedi SK, Sattari S, Jamali F, et al. Ibuprofen racemate and enantiomers: phase diagram, solubility and thermodynamic studies. Int J Pharm. 1992; 87: 95–104.CrossRef
30.
go back to reference Labreque G, Bureau J-P, Reinberg AE. Biological rhythms in the inflammatory response and in the effects of non-steroidal anti-inflammatory drugs. Pharmacol Ther. 1995; 66: 285–300.CrossRef Labreque G, Bureau J-P, Reinberg AE. Biological rhythms in the inflammatory response and in the effects of non-steroidal anti-inflammatory drugs. Pharmacol Ther. 1995; 66: 285–300.CrossRef
31.
go back to reference Ollagnier M, Decousus H, Cherrah Y, et al. Circadian changes in the pharmacokinetics of oral ketoprofen. Clin Pharmacokinet. 1987; 12: 367–78.PubMedCrossRef Ollagnier M, Decousus H, Cherrah Y, et al. Circadian changes in the pharmacokinetics of oral ketoprofen. Clin Pharmacokinet. 1987; 12: 367–78.PubMedCrossRef
32.
go back to reference Kowanko IC, Pownall R, Kanpp AJ, et al. Circadian variations in the signs and symptoms of rheumatoid arthritis and in the therapeutic effectiveness of flurbiprofen at different times of day. Br J Clin Pharmacol. 1981; 11: 477–84.PubMedCrossRef Kowanko IC, Pownall R, Kanpp AJ, et al. Circadian variations in the signs and symptoms of rheumatoid arthritis and in the therapeutic effectiveness of flurbiprofen at different times of day. Br J Clin Pharmacol. 1981; 11: 477–84.PubMedCrossRef
33.
go back to reference Clench J, Reinberg A, Dziewanowska Z, et al. Circadian changes in the bioavailability and effects of indomethacin in healthy subjects. Eur J Clin Pharmacol. 1981; 20: 359–64.PubMedCrossRef Clench J, Reinberg A, Dziewanowska Z, et al. Circadian changes in the bioavailability and effects of indomethacin in healthy subjects. Eur J Clin Pharmacol. 1981; 20: 359–64.PubMedCrossRef
34.
go back to reference Huskisson EC. Chronopharmacology of anti-rheumatic drugs with special reference to indomethacin. In: Huskisson EC, Velo GP, editors. Inflammatory arthropathies. Amsterdam: Excerpta Medica, 1976: 99–105. Huskisson EC. Chronopharmacology of anti-rheumatic drugs with special reference to indomethacin. In: Huskisson EC, Velo GP, editors. Inflammatory arthropathies. Amsterdam: Excerpta Medica, 1976: 99–105.
35.
go back to reference Reinberg A, Levi F. Clinical chronopharmacology with special reference to NSAIDs. Scand J Rheumatol 1995; Suppl. 65: 118–22. Reinberg A, Levi F. Clinical chronopharmacology with special reference to NSAIDs. Scand J Rheumatol 1995; Suppl. 65: 118–22.
36.
go back to reference Jamali F, Kunz-Dober CM. Pain-mediated altered absorption and metabolism of Ibuprofen: an explanation for decreased serum enantiomer concentration after dental surgery. Br J Clin Pharmacol. 1999; 47: 391–6.PubMedCrossRef Jamali F, Kunz-Dober CM. Pain-mediated altered absorption and metabolism of Ibuprofen: an explanation for decreased serum enantiomer concentration after dental surgery. Br J Clin Pharmacol. 1999; 47: 391–6.PubMedCrossRef
37.
go back to reference Kean WF, Buchanan WW. Variables affecting the absorption of non-steroidal anti-inflammatory drugs from the gastro-intestinal tract. Jpn J Rheumatol. 1987; 1(3): 159–70. Kean WF, Buchanan WW. Variables affecting the absorption of non-steroidal anti-inflammatory drugs from the gastro-intestinal tract. Jpn J Rheumatol. 1987; 1(3): 159–70.
38.
go back to reference Anne AP, Halpen SM, Streete PJ, et al. Slow release aspirin in the elderly. J R Soc Med. 1994; 87: 183–4. Anne AP, Halpen SM, Streete PJ, et al. Slow release aspirin in the elderly. J R Soc Med. 1994; 87: 183–4.
39.
go back to reference Verbeeck RK. Pathophysiological factors affecting the pharmacokinetics of nonsteroidal antiinflammatory drugs. J Rheumatol 1988; (Suppl. 17) 15: 44–57. Verbeeck RK. Pathophysiological factors affecting the pharmacokinetics of nonsteroidal antiinflammatory drugs. J Rheumatol 1988; (Suppl. 17) 15: 44–57.
40.
go back to reference Verbeeck RK. Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs. Clin Pharmacokinet. 1990; 19(1): 44–66.PubMedCrossRef Verbeeck RK. Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs. Clin Pharmacokinet. 1990; 19(1): 44–66.PubMedCrossRef
41.
go back to reference Brater DG. Clinical pharmacology of NSAIDs. J Clin Pharmacol. 1988; 28: 518–23.PubMed Brater DG. Clinical pharmacology of NSAIDs. J Clin Pharmacol. 1988; 28: 518–23.PubMed
42.
go back to reference Van Den Ouweland FA, Gribnau FWJ, van Ginneken CAM, et al. Naproxen kinetics and disease activity in rheumatoid arthritis: a within-patient study. Clin Pharmacol Ther. 1988; 43: 79–85.PubMedCrossRef Van Den Ouweland FA, Gribnau FWJ, van Ginneken CAM, et al. Naproxen kinetics and disease activity in rheumatoid arthritis: a within-patient study. Clin Pharmacol Ther. 1988; 43: 79–85.PubMedCrossRef
43.
go back to reference Van Den Ouweland FA, Gribnau FWJ, Tan Y, et al. Hypoalbumin-aemia and naproxen pharmacokinetics in a patient with rheumatoid arthritis. Clin Pharmacokinet. 1986; 11: 511–5.PubMedCrossRef Van Den Ouweland FA, Gribnau FWJ, Tan Y, et al. Hypoalbumin-aemia and naproxen pharmacokinetics in a patient with rheumatoid arthritis. Clin Pharmacokinet. 1986; 11: 511–5.PubMedCrossRef
44.
go back to reference Netter P, Bannwarth B, Royer-Morrot MJ. Recent findings in the pharmacokinetics of non-steroidal anti-inflammatory drugs in synovial fluid. Clin Pharmacokinet. 1989; 17: 145–62.PubMedCrossRef Netter P, Bannwarth B, Royer-Morrot MJ. Recent findings in the pharmacokinetics of non-steroidal anti-inflammatory drugs in synovial fluid. Clin Pharmacokinet. 1989; 17: 145–62.PubMedCrossRef
45.
go back to reference Jalali S, Macfarlane JG, Grace EM, et al. Frequency of administration of short half-life nonsteroidal anti-inflammatory analgesics (NSAIDs): studies with Ibuprofen. Clin Exp Rheumatol. 1986; 4: 91–3.PubMed Jalali S, Macfarlane JG, Grace EM, et al. Frequency of administration of short half-life nonsteroidal anti-inflammatory analgesics (NSAIDs): studies with Ibuprofen. Clin Exp Rheumatol. 1986; 4: 91–3.PubMed
46.
go back to reference Needs CJ, Brooks PM. Clinical Pharmacokinetics of salicylates. Clin Pharmacokinet. 1985; 10: 164–77.PubMedCrossRef Needs CJ, Brooks PM. Clinical Pharmacokinetics of salicylates. Clin Pharmacokinet. 1985; 10: 164–77.PubMedCrossRef
47.
go back to reference Bertin P, Lapique F, Payan E, et al. Sodium naproxen: concentration and effect on inflammatory response mediators in human rheumatoid synovial fluid. Eur J Clin Pharmacol. 1994; 46: 3–7.PubMedCrossRef Bertin P, Lapique F, Payan E, et al. Sodium naproxen: concentration and effect on inflammatory response mediators in human rheumatoid synovial fluid. Eur J Clin Pharmacol. 1994; 46: 3–7.PubMedCrossRef
48.
go back to reference Wax J, Clinger A, Varner P, et al. Relationship of the enterohep-atic cycle to ulcerogenesis in the rat small bowel with flufenamic acid. Gastroenterology. 1970; 58(6): 772–9.PubMed Wax J, Clinger A, Varner P, et al. Relationship of the enterohep-atic cycle to ulcerogenesis in the rat small bowel with flufenamic acid. Gastroenterology. 1970; 58(6): 772–9.PubMed
49.
go back to reference Wright MR, Davies NM, Jamali F. Toxicokinetics of indomethacin-induced intestinal permeability in the rat. Pharmacol Res. 1997; 35(6): 499–504.PubMedCrossRef Wright MR, Davies NM, Jamali F. Toxicokinetics of indomethacin-induced intestinal permeability in the rat. Pharmacol Res. 1997; 35(6): 499–504.PubMedCrossRef
50.
go back to reference Davies NM, Wright MR, Russell AS, et al. Effect of the enantiomers of flurbiprofen, Ibuprofen, and ketoprofen on intestinal permeability. J Pharm Sci. 1996; 85(11): 1170–73.PubMedCrossRef Davies NM, Wright MR, Russell AS, et al. Effect of the enantiomers of flurbiprofen, Ibuprofen, and ketoprofen on intestinal permeability. J Pharm Sci. 1996; 85(11): 1170–73.PubMedCrossRef
51.
go back to reference Wright MR, Davies NM, Jamali F. Rationale for the development of stereochemically pure enantiomers: are the R enantiomers of chiral nonsteroidal anti-inflammatory drugs inactive? J Pharm Sci. 1994; 83: 911–2.PubMedCrossRef Wright MR, Davies NM, Jamali F. Rationale for the development of stereochemically pure enantiomers: are the R enantiomers of chiral nonsteroidal anti-inflammatory drugs inactive? J Pharm Sci. 1994; 83: 911–2.PubMedCrossRef
52.
go back to reference Paulus HE. Postmarketing surveillance of nonsteroidal anti-inflammatory drugs. Arthritis Rheum. 1986; 28: 1168–9.CrossRef Paulus HE. Postmarketing surveillance of nonsteroidal anti-inflammatory drugs. Arthritis Rheum. 1986; 28: 1168–9.CrossRef
53.
go back to reference Adams SS. Non-steroidal antiinflammatory drugs, plasma half-life and adverse reactions. Lancet 1987; II: 1204–5.CrossRef Adams SS. Non-steroidal antiinflammatory drugs, plasma half-life and adverse reactions. Lancet 1987; II: 1204–5.CrossRef
54.
go back to reference Adams SS. NSAIDs, plasma half-life and adverse reactions. Lancet 1988; I: 653–4.CrossRef Adams SS. NSAIDs, plasma half-life and adverse reactions. Lancet 1988; I: 653–4.CrossRef
55.
go back to reference Adams SS. The propionic acids: a personal perspective. J Clin Pharmacol. 1992; 32: 317–23.PubMed Adams SS. The propionic acids: a personal perspective. J Clin Pharmacol. 1992; 32: 317–23.PubMed
56.
go back to reference Collier DSJ, Pain JA. Nonsteroidal antiinflammatory drugs and hospital admission for perforated peptic ulcer. Lancet 1985; II: 380–2. Collier DSJ, Pain JA. Nonsteroidal antiinflammatory drugs and hospital admission for perforated peptic ulcer. Lancet 1985; II: 380–2.
57.
go back to reference Furst DE. Clinical significance of long versus short serum half-lives in NSAIDs. In: Famaey JP, Paulus HE, editors. Therapeutic application of NSAIDs: subpopulations and new formulations. Oxford: Oxford University Press, 1998: 359–83. Furst DE. Clinical significance of long versus short serum half-lives in NSAIDs. In: Famaey JP, Paulus HE, editors. Therapeutic application of NSAIDs: subpopulations and new formulations. Oxford: Oxford University Press, 1998: 359–83.
58.
go back to reference Albengres E, Pinquier JL, Riant P, et al. Pharmacological criteria for risk-benefit evaluation of NSAIDs. Scand J Rheumatol 1988; Suppl. 73: 3–15.CrossRef Albengres E, Pinquier JL, Riant P, et al. Pharmacological criteria for risk-benefit evaluation of NSAIDs. Scand J Rheumatol 1988; Suppl. 73: 3–15.CrossRef
59.
go back to reference Smith GL, Goulbourn RA, Burt RAP, et al. Preliminary studies of absorption and excretion of benoxaprofen in man. Br J Clin Pharmacol. 1977; 4: 585–90.PubMedCrossRef Smith GL, Goulbourn RA, Burt RAP, et al. Preliminary studies of absorption and excretion of benoxaprofen in man. Br J Clin Pharmacol. 1977; 4: 585–90.PubMedCrossRef
60.
go back to reference Hamdy RC, Murnane B, Perera N, et al. The pharmacokinetics of benoxaprofen in elderly subjects. Eur J Rheumatol Inflamm. 1982; 5: 69–75.PubMed Hamdy RC, Murnane B, Perera N, et al. The pharmacokinetics of benoxaprofen in elderly subjects. Eur J Rheumatol Inflamm. 1982; 5: 69–75.PubMed
61.
go back to reference Taggart S, Alderdice JM. Fatal jaundice in elderly patients taking benoxaprofen [letter]. Br Med J. 1982; 284: 1372.CrossRef Taggart S, Alderdice JM. Fatal jaundice in elderly patients taking benoxaprofen [letter]. Br Med J. 1982; 284: 1372.CrossRef
62.
go back to reference Duthie A, Nicholls A, Freeth M, et al. Fatal cholestatic jaundice in elderly patients taking benoxaprofen [letter]. Br Med J. 1982; 285: 62.CrossRef Duthie A, Nicholls A, Freeth M, et al. Fatal cholestatic jaundice in elderly patients taking benoxaprofen [letter]. Br Med J. 1982; 285: 62.CrossRef
63.
go back to reference Karim A. Inverse nonlinear pharmacokinetics of total and protein unbound drug (Oxaprozin): clinical and pharmacokinetic implications. J Clin Pharmacol. 1996; 36: 985–97.PubMedCrossRef Karim A. Inverse nonlinear pharmacokinetics of total and protein unbound drug (Oxaprozin): clinical and pharmacokinetic implications. J Clin Pharmacol. 1996; 36: 985–97.PubMedCrossRef
64.
go back to reference Upton RA, Williams RL, Kelly J, et al. Naproxen pharmacokinetics in the elderly. Br J Clin Pharmacol. 1984; 18: 207–14.PubMedCrossRef Upton RA, Williams RL, Kelly J, et al. Naproxen pharmacokinetics in the elderly. Br J Clin Pharmacol. 1984; 18: 207–14.PubMedCrossRef
65.
go back to reference Day RO, Furst DE, Droomgoole SH, et al. Relationship of serum naproxen concentration to efficacy in rheumatoid arthritis. Clin Pharm Ther. 1982; 31: 733–40.CrossRef Day RO, Furst DE, Droomgoole SH, et al. Relationship of serum naproxen concentration to efficacy in rheumatoid arthritis. Clin Pharm Ther. 1982; 31: 733–40.CrossRef
66.
go back to reference Dunagan FM, McGill PE, Kelman AW, et al. Naproxen dose and concentration: response relationship in rheumatoid arthritis. Br J Rheumatol. 1988; 27: 48–53.PubMedCrossRef Dunagan FM, McGill PE, Kelman AW, et al. Naproxen dose and concentration: response relationship in rheumatoid arthritis. Br J Rheumatol. 1988; 27: 48–53.PubMedCrossRef
67.
go back to reference Day RO, Graham GG, Williams KM, et al. Variability in response to NSAIDs. Fact or fiction? Drugs. 1988; 36: 643–51.PubMed Day RO, Graham GG, Williams KM, et al. Variability in response to NSAIDs. Fact or fiction? Drugs. 1988; 36: 643–51.PubMed
68.
go back to reference Gérard MJ. Individual variation in the response to nonsteroidal anti-inflammatory drugs. Rev Rhum Mal Osteoartic. 1988; 55(10): 735–9.PubMed Gérard MJ. Individual variation in the response to nonsteroidal anti-inflammatory drugs. Rev Rhum Mal Osteoartic. 1988; 55(10): 735–9.PubMed
69.
go back to reference Day RO, Francis H, Vial J, et al. Naproxen concentrations in plasma and synovial fluid and effects on Prostanoid concentrations. J Rheumatol. 1995; 22: 2295–303.PubMed Day RO, Francis H, Vial J, et al. Naproxen concentrations in plasma and synovial fluid and effects on Prostanoid concentrations. J Rheumatol. 1995; 22: 2295–303.PubMed
70.
go back to reference Greenan DW, Aarons L, Siddiqui M, et al. Dose-response study with Ibuprofen in rheumatoid arthritis: clinical and pharmacokinetic findings. Br J Clin Pharmacol. 1983; 15: 311–6.CrossRef Greenan DW, Aarons L, Siddiqui M, et al. Dose-response study with Ibuprofen in rheumatoid arthritis: clinical and pharmacokinetic findings. Br J Clin Pharmacol. 1983; 15: 311–6.CrossRef
71.
go back to reference Greenan DM, Ferry DG, Ashworth ME, et al. The aspirin-ibuprofen interaction in rheumatoid arthritis. Br J Clin Pharmacol. 1979; 8: 497–503.CrossRef Greenan DM, Ferry DG, Ashworth ME, et al. The aspirin-ibuprofen interaction in rheumatoid arthritis. Br J Clin Pharmacol. 1979; 8: 497–503.CrossRef
72.
go back to reference Bradley JD, Rudy AC, Katz BP, et al. Correlation of serum concentrations of Ibuprofen stereoisomers with clinical response in the treatment of hip and knee Osteoarthritis. J Rheumatol. 1992; 19(1): 130–4.PubMed Bradley JD, Rudy AC, Katz BP, et al. Correlation of serum concentrations of Ibuprofen stereoisomers with clinical response in the treatment of hip and knee Osteoarthritis. J Rheumatol. 1992; 19(1): 130–4.PubMed
73.
go back to reference Neupert W, Brugger R, Euchenhofer C, et al. Effects of Ibuprofen enantiomers and its coenzyme A thioester on human Prostaglandin endoperoxide synthases. Br J Pharmacol. 1997; 122: 487–92.PubMedCrossRef Neupert W, Brugger R, Euchenhofer C, et al. Effects of Ibuprofen enantiomers and its coenzyme A thioester on human Prostaglandin endoperoxide synthases. Br J Pharmacol. 1997; 122: 487–92.PubMedCrossRef
74.
go back to reference Laska EM, Sunshine A, Marrero I. The correlation between blood levels of Ibuprofen and analgesic response. Clin Pharmacol Ther. 1986; 40(1): 1–7.PubMedCrossRef Laska EM, Sunshine A, Marrero I. The correlation between blood levels of Ibuprofen and analgesic response. Clin Pharmacol Ther. 1986; 40(1): 1–7.PubMedCrossRef
75.
go back to reference Ceppi Monti N, Gazzaniga A, Gianesello V, et al. Activity and pharmacokinetics of a new oral dosage form of soluble Ibuprofen. Arzneimittel Forschung. 1992; 42: 556–9.PubMed Ceppi Monti N, Gazzaniga A, Gianesello V, et al. Activity and pharmacokinetics of a new oral dosage form of soluble Ibuprofen. Arzneimittel Forschung. 1992; 42: 556–9.PubMed
76.
go back to reference Kauffman RE, Nelson MV. Effect of age on Ibuprofen pharmacokinetics and antipyretic response. J Pediatr. 1992; 121: 969–73.PubMedCrossRef Kauffman RE, Nelson MV. Effect of age on Ibuprofen pharmacokinetics and antipyretic response. J Pediatr. 1992; 121: 969–73.PubMedCrossRef
77.
go back to reference Wynne HA, Rawlins MD. Are systemic levels of nonsteroidal anti-inflammatory drugs relevant to acute upper gastrointestinal haemorrhage? Eur J Clin Pharmacol. 1993; 44: 309–13.PubMedCrossRef Wynne HA, Rawlins MD. Are systemic levels of nonsteroidal anti-inflammatory drugs relevant to acute upper gastrointestinal haemorrhage? Eur J Clin Pharmacol. 1993; 44: 309–13.PubMedCrossRef
78.
go back to reference Davies NM, Jamali F. Influence of flurbiprofen dosage form on gastroenteropathy in the rat: evidence of shift in the toxicity site. Pharm Res. 1997; 11(6): 255–9. Davies NM, Jamali F. Influence of flurbiprofen dosage form on gastroenteropathy in the rat: evidence of shift in the toxicity site. Pharm Res. 1997; 11(6): 255–9.
79.
go back to reference Held H. Elimination shalbwertszeiten und serum protein bindung des antirheumatikums naproxen bei niereninsuffizienz. Z Rheumatol. 1979; 38: 111–9.PubMed Held H. Elimination shalbwertszeiten und serum protein bindung des antirheumatikums naproxen bei niereninsuffizienz. Z Rheumatol. 1979; 38: 111–9.PubMed
80.
go back to reference Ritch AES, Perera WNR, Jones CJ. Pharmacokinetics of azapropazone in the elderly. Br J Clin Pharmacol. 1982; 14: 116–9.PubMedCrossRef Ritch AES, Perera WNR, Jones CJ. Pharmacokinetics of azapropazone in the elderly. Br J Clin Pharmacol. 1982; 14: 116–9.PubMedCrossRef
81.
go back to reference Meffin PJ. The effects of renal dysfunction on the disposition of NSAIDs forming acyl-glucuronides. Agents Actions. 1985; 17: 85–9. Meffin PJ. The effects of renal dysfunction on the disposition of NSAIDs forming acyl-glucuronides. Agents Actions. 1985; 17: 85–9.
82.
go back to reference Brater CG. Drug-drug and drug-disease interactions with non-steroidal anti-inflammatory drugs. Am J Med 1986; 80 (Suppl. 1A): 62–77.PubMedCrossRef Brater CG. Drug-drug and drug-disease interactions with non-steroidal anti-inflammatory drugs. Am J Med 1986; 80 (Suppl. 1A): 62–77.PubMedCrossRef
83.
go back to reference Richardson CJ, Blocka KLN, Ross SG, et al. Effects of age and sex on piroxicam disposition. Clin Pharmacol Ther. 1985; 37: 13–8.PubMedCrossRef Richardson CJ, Blocka KLN, Ross SG, et al. Effects of age and sex on piroxicam disposition. Clin Pharmacol Ther. 1985; 37: 13–8.PubMedCrossRef
84.
go back to reference Woodhouse KW, Wynne H. The pharmacokinetics of non-steroidal anti-inflammatory drugs in the elderly. Clin Pharmacokinet. 1987; 12: 111–2.PubMedCrossRef Woodhouse KW, Wynne H. The pharmacokinetics of non-steroidal anti-inflammatory drugs in the elderly. Clin Pharmacokinet. 1987; 12: 111–2.PubMedCrossRef
85.
go back to reference Orme M. NSAIDs in the healthy elderly. In: Famaey JP, Paulus HE, editors. Therapeutic applications of NSAIDs. New York (NY): Marcel Dekker, 1992: 191–210. Orme M. NSAIDs in the healthy elderly. In: Famaey JP, Paulus HE, editors. Therapeutic applications of NSAIDs. New York (NY): Marcel Dekker, 1992: 191–210.
86.
go back to reference Montamat SC, Cusack BJ, Vestal RE. Management of drug therapy in the elderly. Med Intell. 1989; 321(5): 303–9. Montamat SC, Cusack BJ, Vestal RE. Management of drug therapy in the elderly. Med Intell. 1989; 321(5): 303–9.
87.
go back to reference Brouwers JRBJ, de Smet PAGM. Pharmacokinetic-pharmaco-dynamic drug interactions with nonsteroidal anti-inflammatory drugs. Clin Pharmacokinet. 1994; 27(6): 462–85.PubMedCrossRef Brouwers JRBJ, de Smet PAGM. Pharmacokinetic-pharmaco-dynamic drug interactions with nonsteroidal anti-inflammatory drugs. Clin Pharmacokinet. 1994; 27(6): 462–85.PubMedCrossRef
Metadata
Title
Choosing the Right Nonsteroidal Anti-Inflammatory Drug for the Right Patient
A Pharmacokinetic Approach
Authors
Dr Neal M. Davies
Neil M. Skjodt
Publication date
01-05-2000
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 5/2000
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.2165/00003088-200038050-00001

Other articles of this Issue 5/2000

Clinical Pharmacokinetics 5/2000 Go to the issue